Literature DB >> 8645591

A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.

P Pronzato1, G Bertelli, A Vigani, F Vaira.   

Abstract

We have evaluated the feasibility of an increase in dose intensity of the cisplatin, epidoxorubicin and cyclophosphamide (PEC) regimen, with granulocyte colony-stimulating factor (G-CSF) support, in 22 patients with advanced ovarian cancer. Twenty-one patients (95.4%) received six cycles of treatment: of these, 13 (61.9%) were also able to repeat cycles every 14 days as planned. Marrow toxicity was similar to that observed during conventional treatments. No severe mucositis or thrombocytopenia was observed. A clinical complete response was observed in 9 out of 16 evaluable patients (56.2%).

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8645591      PMCID： PMC2074481          DOI： 10.1038/bjc.1996.270

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  9 in total

1.  Average relative dose intensity and the impact on design of clinical trials.

Authors:  W M Hryniuk
Journal:  Semin Oncol       Date:  1987-03       Impact factor: 4.929

2.  Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

Authors:  J P Neijt; W W ten Bokkel Huinink; M E van der Burg; A T van Oosterom; P H Willemse; A P Heintz; M van Lent; J B Trimbos; J Bouma; J B Vermorken
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

Review 3.  The importance of dose intensity in chemotherapy of metastatic breast cancer.

Authors:  W Hryniuk; H Bush
Journal:  J Clin Oncol       Date:  1984-11       Impact factor: 44.544

4.  Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

Authors:  J Crawford; H Ozer; R Stoller; D Johnson; G Lyman; I Tabbara; M Kris; J Grous; V Picozzi; G Rausch
Journal:  N Engl J Med       Date:  1991-07-18       Impact factor: 91.245

5.  Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer.

Authors:  S B Kaye; C R Lewis; J Paul; I D Duncan; H K Gordon; H C Kitchener; D J Cruickshank; R J Atkinson; M Soukop; E M Rankin
Journal:  Lancet       Date:  1992-08-08       Impact factor: 79.321

6.  Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.

Authors:  J L Gabrilove; A Jakubowski; H Scher; C Sternberg; G Wong; J Grous; A Yagoda; K Fain; M A Moore; B Clarkson; Herbert F Oettgen; Kirby Alton; Karl Welte; Lawrence Souza
Journal:  N Engl J Med       Date:  1988-06-02       Impact factor: 91.245

7.  The impact of received dose intensity on the outcome of advanced ovarian cancer.

Authors:  L Repetto; M Pace; S Mammoliti; M Bruzzone; S Chiara; C Oliva; T Guido; P F Conte; E Campora; A Rubagotti
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

8.  The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.

Authors:  L Levin; W Hryniuk
Journal:  Semin Oncol       Date:  1987-12       Impact factor: 4.929

9.  The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer.

Authors:  M H Bronchud; A Howell; D Crowther; P Hopwood; L Souza; T M Dexter
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640
  9 in total
  3 in total

1.  Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan.

Authors:  Michiya Kobayashi; Koji Oba; Junichi Sakamoto; Ken Kondo; Naoki Nagata; Takehiro Okabayashi; Tsutomu Namikawa; Kazuhiro Hanazaki
Journal:  Gastric Cancer       Date:  2007-02-23       Impact factor: 7.370

2.  Combination chemotherapy with nedaplatin and cyclophosphamide in human ovarian cancer model.

Authors:  N Uchida; H Yoshida; H Yamada; T Wada; K Daikatsu; I Ikeuchi; R Maekawa; K Sugita; T Yoshioka
Journal:  Jpn J Cancer Res       Date:  1999-08

3.  High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.

Authors:  P Pronzato; R Lionetto; F Botto; F Pensa; A Tognoni
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.